By Stephen Nakrosis 
 

Gilead Sciences Inc. and Galapagos NV on Wednesday said results from a trial of their filgotinib 200 mg in adult patients with moderately to severely active ulcerative colitis showed it had "achieved all primary endpoints in the study, inducing clinical remission at Week 10 and maintaining clinical remission at Week 58 in a significantly higher proportion of patients compared with placebo."

The companies said the Phase 2b/3 Selection trial evaluated "the efficacy and safety of the investigational, oral, once-daily, selective JAK1 inhibitor filgotinib in 1,348 biologic-naïve or biologic-experienced adult patients with moderately to severely active ulcerative colitis."

The companies also said filgotinib 100 mg didn't achieve statistically significant clinical remission at Week 10.

Detailed results from the trial will be submitted for presentation at a future scientific conference, the companies said.

 

--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

 

(END) Dow Jones Newswires

May 20, 2020 16:53 ET (20:53 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jul 2020 to Aug 2020 Click Here for more Gilead Sciences Charts.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Aug 2019 to Aug 2020 Click Here for more Gilead Sciences Charts.